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AKTPoly (ADP-ribose) polymerase (PARP) enzymes play a key role in the cellular machinery responsible for DNA re-
pair. Dehydroxymethylepoxyquinomicin (DHMEQ), a new inhibitor of NF-κB, induces oxidative stress and DNA
damage. The effects of DHMEQ in combination with Olaparib (PARP inhibitor) were studied on hepatocellular
carcinoma (HCC) cells. The DHMEQ–Olaparib combination synergistically inhibited cell viability, cell prolifera-
tion and colony formation of Hep3B, but had additive effects on Huh7 cells. The synergistic effects of the combi-
nation correlatedwith increased apoptosis, caspase 3/7 activity and PARP cleavage. There was an induction of an
endoplasmic reticulum (ER) stress response with signiﬁcant up-regulation of CHOP and TRB3 genes and splicing
of XBP1 mRNA in Hep3B cells but not in Huh7 cells. Silencing of the TRB3 mRNA in Hep3B cells reversed the re-
duction in viability caused byDHMEQ–Olaparib treatment, while depletion of unsplicedXBP1mRNA inDHMEQ–
Olaparib-treatedHuh7 cells reduced viability. ROS productionwas increased afterDHMEQ–Olaparib treatment of
Hep3B, which caused DNA damage by an accumulation of γH2AX, increased AKT phosphorylation and reduced
cell viability. The combination reduced Rad51 nuclear foci in Hep3B cells (not Huh7 cells), and silencing of
Rad51 enhanced sensitivity of Huh7 cells to the DHMEQ–Olaparib combination. Knockdown of AKT in Hep3B
cells restored the number of Rad51 nuclear foci after DHMEQ–Olaparib treatment. In summary, the DHMEQ–
Olaparib combination induced ROS production,which killedHCC cells via DNAdamage that could not be repaired
by Rad51.
S U M M A R Y
PARPs andNF-κB are frequently deregulated inHCC. The DHMEQ–Olaparib combination exerted synergistic anti-
tumour effects on HCC cells through ROS production via DNA damage that could not be repaired by Rad51. This
suggested that the DHMEQ–Olaparib combination could be used to treat tumours that were resistant to Olaparib
treatment.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Nuclear transcription factor-κB (NF-κB) has been implicated
in carcinogenesis and is a potential target for cancer prevention
[1], while several reports indicate that NF-κB is constitutively
activated in a variety of cancer cells (including HCC) [2].
Dehydroxymethylepoxyquinomicin (DHMEQ) is a novel NF-κB inhibi-
tor that induces apoptosis and cell-cycle arrest in several cancer cellomicin; ROS, Reactive Oxygen
uclear transcription factor-κB;
protein response
and Molecular Immunology
Via Ugo La Malfa 153, 90146
9548.types [3,4], and promotes ROS generation, which causes genotoxic
DNA damage in human liver cells [5,6].
Poly (ADP ribose) polymerases (PARPs) are a family of enzymes that
share a catalytic PARP homology domain and the ability to poly-ADP-
ribosylate protein substrates. Among them, PARP1 and PARP2 are
involved in base excision repair (BER) and single strand break (SSB)
repair. When replication forks encounter SSBs, they generate double-
strand breaks (DBSs) that need to be repaired by homologous recombi-
nation (HR). PARP1 and PARP2 bind to nicks and strand-breaks in DNA
(including intermediates of BER or HR) and become catalytically-
activated, synthesizing PAR polymers from NAD+ and poly ADP-
ribosylating themselves and other proteins involved in DNA repair
and chromatin remodelling. Because of the negatively charged PARP
polymers, extensive autoPARylation of PARP1 and PARP2 leads to
their dissociation from DNA, which is required for the completion of
2663N. Lampiasi et al. / Biochimica et Biophysica Acta 1843 (2014) 2662–2673DNA repair [7]. Some PARP inhibitors mimic NAD+ blocking of PARP
catalytic activity, in turn preventing PARylation of PARP1 and PARP2
and their release from DNA, which prevents access of other repair
proteins to the site of DNA damage. Therefore, when PARPs are
inhibited, SSB degenerates and DNA damage is repaired by homologous
recombination (HR). PARP inhibition results in the accumulation of
recombinogenic substrates marked by Rad51 and phosphorylated
H2AX (γH2AX) nuclear foci [8,9]. Consequently, cancer cells deﬁcient
in BRCA1, BRCA2, Fanconi anaemia (FA), PTEN or other HR-related
genes are hypersensitive to PARP inhibitors [10–13].
PARP inhibitors are one of themost promising new therapeutic anti-
cancer drugs, either singly or in combinationwith other DNA-damaging
agents, including agents that cause genotoxic DNA damage. Different
PARP inhibitors have been used alone or in combination with various
chemotherapeutic agents, especially in triple-negative breast cancer
(TNBC) patients or for other solid tumours [14]. Olaparib (AZD2281),
veliparib (ABT-888), iniparib (BSI-201) and niraparib (MK-4827) are
PARP inhibitors in advanced clinical trials. They are efﬁcacious PARP cat-
alytic inhibitorswith lownanomolar IC50 values in triple negative breast
cancer (TNBC) cells [15,16]. However, few studies have been performed
with hepatocellular carcinomas, and little is known about molecular
mechanisms of PARP inhibitors in HCC.
In this study,we investigated the hypothesis that inducing genotoxic
DNA damagewith DHMEQ and targeting the enzymatic activity of PARP
with Olaparib could synergistically kill HCC cells.
2. Materials and methods
2.1. Reagents and cell culture
DHMEQ was synthesized as previously described [17]. N-acetyl-L-
cysteine (NAC) and 3-methyladenine (3-MA) were purchased from
Sigma-Aldrich (Milan, Italy). Olaparib was purchased from Selleckchem
(Houston, Texas, USA) and was dissolved in dimethyl sulphoxide
(DMSO), theﬁnal DMSO concentration never exceeded 0.1% inmedium.
U0126 was purchased from Enzo Life Science (Vinci-Biochem, Vinci, FI,
Italy). The HCC cell lines (Huh7 and Hep3B) used in this studywere of a
low passage number and maintained in RPMI supplemented with 10%
inactivated foetal bovine serum, 0.01% glutamine, 1% penicillin/strepto-
mycin as previously described [5,6]. Huh7 cells used in this studywere a
gift from Prof. M. Levrero (Department of Internal Medicine, Sapienza
University, Rome, Italy) and the Hep3B cells used were a gift from
Prof. O. Bussolati (Unit of General and Clinical Pathology, Department
of Experimental Medicine, University of Parma, Parma, Italy). All cell
lines were conﬁrmed negative for mycoplasma in 2013.
2.2. MTS and BrdU incorporation assays
Cell viability was evaluated using the MTS assays, which were
performed using the CellTiter Aqueous One Solution reagent (Promega
Corporation,Madison,WI, USA) as previously reported [5]. Cell prolifer-
ation was determined by estimating the amount of BrdU incorporation
into DNA by a colorimetric immunoassay (Roche Diagnostics GmbH,
Mannheim, Germany) as previously reported [5]. Data were expressed
as percent of control and were the mean ± SD of three separate exper-
iments, each performed in triplicate. In experiments with NAC, cells
were pre-treated with NAC (2 mM) for 2 h and then treated with
DHMEQ or Olaparib alone or in combination for a 24 additional hours
in the presence of NAC. CalcuSyn software (Biosoft) was used to calcu-
late the combination index (CI), where a CI b 1 indicated synergy, ~1
indicated an additive effect and N1 indicated antagonism.
2.3. Clonogenic assay
Cells (1× 103)were plated in six-well plates, allowed to attach over-
night and treated with DHMEQ and/or Olaparib (or vehicle) for 24 h.The cells were washed with inhibitor-free medium and allowed to
grow for 14 days under inhibitor-free conditions, after which, colonies
containing more than 50 cells were counted by light microscopy. Rela-
tive colony formation was the ratio of the average colony number for
DHMEQ–Olaparib-treated cells compared to the average number of col-
onies in cells treated with solvent (DMSO). All experiments were per-
formed in duplicate and repeated twice.
2.4. Western blot analysis
Whole cell lysates were obtained using RIPA buffer (Cell Signaling
Technologies Inc., Beverly, MA, USA). Equivalent amounts of protein
(30 μg) from total cell lysates were subjected to SDS-polyacrylamide
gel electrophoresis (PAGE) and the proteins were transferred onto
nitrocellulosemembrane (Millipore, Temecula, CA, USA). After blocking
with 3% bovine serum albumin (BSA) for 1 h themembraneswere incu-
batedwith primary antibodies raised againstβ-actin (Sigma-Aldrich Srl,
Milan, Italy), phospho-Akt (Santa Cruz Biotechnology Inc., Heidelberg,
Germany), PARP, AKT, phospho-ERK1/2, Rad51, γH2AX, LC3I/II and
Bcl2 (Cell Signaling Technologies Inc., Beverly, MA, USA). Densitometry
analyses were conducted using the Quantity One software (Bio-Rad).
Incubation with polyclonal mouse antihuman β-actin antibody was
performed for comparative control.
2.5. Caspase activity assays
Brieﬂy, cells were treated with or without DHMEQ and Olaparib
alone or in combination for 24 h and then caspase activities were
measured using the Caspase-Glo® 3/7 and Caspase-Glo® 8 assay kits
(Promega, Milan, Italy) as previously reported [5].
2.6. Detection of apoptosis
The DeadEnd Colorimetric terminal deoxynucleotidyl transferase
dUTP nick end-labeling (TUNEL) System technique was performed as
suggested by the supplier (Promega Corporation, Madison, WI, USA).
The number of apoptotic cells was determined by counting the percent-
age of brown-colour positive cells. At least 100 cells from two different
cell preparationswere counted for each condition. Cells were visualized
with an Axioskop microscope (Zeiss, Germany).
2.7. Semiquantitative-PCR (sq-PCR) and quantitative Real-Time PCR
(q-PCR)
Total RNAwas isolated using Trizol (Invitrogen Carlsbad, CA) as rec-
ommended by the supplier. Semiquantitative PCRwas performed using
speciﬁc 5′ and 3′ primers which generated speciﬁc bands for XBP1 for-
ward (CCTTGTAGTTGAGAACCAGG) and reverse (GGGGCTTGGTATATAT
GTGG); HKR forward (CTGTGTCCTTGGAGAAAGCTG) and reverse
(GTGTTTCTACGATCGCTCCAG); TRB3 forward (GCCACTGCCTCCCGTC
TTG) and reverse (GCTGCCTTGCCCGAGTATGA); IL-6 forward (GAGG
TGTGAGTGGGATGGTGG) and reverse (GCTGCATCTGATTTGCCAAC);
β-actin forward (CACCACACCTTCTACAATGAGC) and reverse (GAGGAT
CTTCATGAGGTAGTCAGT). Expression of selected genes was quantiﬁed
by quantitative SYBR Green ﬂuorescence (Qiagen, Milan, Italy) Real-
Time PCR (qPCR) using the StepOnePlus (Applied Biosystems, Carlsbad,
CA, USA). QuantiTect Primer assays for Bcl2 (QT00025011), CHOP
(QT00082278) and TRB3 (QT00088543) were purchased by Qiagen
(Milano, Italy) and ampliﬁed as recommended. Relative expression
was calculated using the comparative Ct method. Relative quantity of
the gene of interest was calculated as ratio of drug-treated samples ver-
sus control (DMSO) and corrected by the quantiﬁed expression level of
β-actin (QT00095431). The results shown were the mean ± SD of two
experiments, each performed in triplicate.
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Cells were treated for 24 h with DHMEQ and/or Olaparib and
ﬁxed with 3.7% paraformaldehyde for 15 min. Then cells were in-
cubated with primary antibodies for 1 h at room temperature
(γH2AX 1:200, Rad51 1:50), incubated with secondary antibodies
for 1 h at room temperature (Alexa Fluor 488 goat anti rabbit
1:500, Invitrogen) and nuclear foci scored by ﬂuorescence microsco-
py (Zeiss Axioskop, Germany).2.9. Small interfering RNA (siRNA) transfection
Cells were transfected with Rad51 siRNA, TRB3 siRNA, PARP1 siRNA,
HKR siRNA, XBP1 siRNA, AKT1 siRNA and Non-Correlated (NC) siRNA
(Qiagen, Milan, Italy) as previously reported [5] In brief, cells (2 × 105)
were seeded onto 60-mm dishes in medium without antibiotics; 24 h
later, the transfection of siRNAs was carried out with Lipofectamine
RNAiMAX (Invitrogen). All transfections were carried out with 20 μM
duplex siRNA in medium without FBS and antibiotics. After 24 h, cells
were split into 96-well plates to perform MTS and BrdU assays and in
60-mm dishes for mRNA and protein analysis. After 24 h (48 h after
transfection), cells were untreated or treated for 24 h with DHMEQ
and/or Olaparib and cell viability, cell proliferation and Rad51 foci stain-
ing performed as described above.2.10. Evaluation of Reactive Oxygen Species production
The intracellular accumulation of ROS was evaluated using the ﬂuo-
rescent probe 5-(and-6)-carboxy-2′, 7′-dichlorodihydroﬂuorescein
diacetate (Carboxy-H2DCFDA) (Invitrogen Carlsbad, CA, USA; n.
C-400) as previously reported [6]. In brief, cells (5 × 103) were seeded
onto 96-well plates in complete medium. After 24 h, cells were untreat-
ed or treated for 24 h with DHMEQ and/or Olaparib. The cells were
washedwith phosphate buffer saline (PBS)with Ca andMg and then in-
cubated for 15 min at 37 °C in the dark with ﬂuorescent probe (10 μM).
Then the cells were washed twice with PBS with Ca and Mg and ROS
observed by ﬂuorescence microscopy (Zeiss Axioskop, Germany).2.11. Statistical analysis
Statistical analysis was performed using the Student's T test
(two-tailed). The criterion for statistical signiﬁcance was p b 0.05.Fig. 1. The effects of the DHMEQ–Olaparib combination on HCC cells. (A) Cells were treated for
by MTS assays. The DHMEQ−Olaparib combination showed synergistic inhibition of cell viabil
indicated above the bar. Data are expressed as percent cell growth and are the mean ± SD o
**p b 0.01 versus each agent alone. (B) Cells were treated for 24 h with DHMEQ (μg/ml) or Ola
and surviving colonies stained and counted. Data are expressed as percent of control cell colo
in duplicate). *p b 0.05 versus each agent alone. (C) Cells were treated with the indicated conc
proliferation was assessed by the BrdU assay. Data are expressed as percent cell proliferation
triplicate). **p b 0.01 versus each agent alone. The DHMEQ–Olaparib combination showed syn
combination index (CI) values are indicated above the bar. (D) Cells were treated for 24 h wi
was determined by caspase assays. Data are expressed as fold increase from untreated cells an
licate. *p b 0.05 versus each agent alone. (E) Cellswere treatedwithDHMEQ(μg/ml) or Olaparib
es in Bcl-2 expression level were analysed bywestern blotting. The numbers represent fold of B
represent two independent representative experiments. (F) Expression of Bcl2 mRNA was ana
samples versus control (DMSO) and corrected by the quantiﬁed expression level of β-actin. Th
**p b 0.01 versus each agent alone. (Right) Expression of IL-6 mRNA was analysed by semiqua
the expression of β-actin for all the samples. The results shown are the means ± SD of two ex
DHMEQ (μg/ml) and Olaparib (μM) either alone or in combination and apoptotic cells were
Bar charts show the percentage of DHMEQ–Olaparib-induced apoptotic cells. Data are expre
50 μM **p b 0.01 versus each agent alone. (H) Hep3B cells were treated for 24 h with DHMEQ
were assessed by RT-PCR semi-quantitative analysis. The data represent two independent exper
siRNA (siRNA NC) or Harakiri siRNA (siRNA HKR). (Right) RT-PCR semi-quantitative analysis o
with DHMEQ (μg/ml) or Olaparib (μM)alone or in combination and cell viabilitywas assessed by
performed in triplicate. *p b 0.05 versus siRNA NC.3. Results
3.1. DHMEQ–Olaparib treatment reduced cell viability, cell proliferation
and colony formation in addition to inducing apoptosis in Hep3B cells
To test whether inhibiting the enzymatic activities of PARP after
induction of DNA damage by DHMEQ could inhibit HCC cell viability,
two human HCC cell lines (Huh7 and Hep3B) were treated with
different concentrations of DHMEQ–Olaparib. Fig. S1A shows that the
cell lines were resistant to Olaparib but were sensitive to DHMEQ
(Fig. S1B). Then we combined the IC90 and/or the IC70 (data not
shown) and/or the IC30 (data not shown) of DHMEQ and Olaparib and
calculated combination index (CI). The IC90 of DHMEQ and Olaparib
(Fig. 1) combination signiﬁcantly suppressed cell viability (A), colony
formation (B), and cell proliferation (C) in both cell lines, however,
the combination showed a synergistic effect in Hep3B cells and an
additive effect in Huh7 cells (according to the combination index).
To investigate the mechanisms of the synergistic/additive effects on
HCC cells, cells were treated with single drugs or the combination for
24 h and caspase activity quantiﬁed. Effector caspase-3/7 was signiﬁ-
cantly activated in Hep3B cells by the combination treatment (Fig. 1D),
suggesting activation of intrinsic apoptotic pathways, while caspase
activity in Huh7 cells was not detected (Fig. 1D). Caspase-8 (extrinsic ap-
optotic pathway) activation was not seen in either cell line (data
not shown).
The expressions of apoptosis-related proteins as well as PARP cleav-
age (a caspase-3/7 substrate) were analysed. The combination treat-
ment resulted in increased PARP cleavage in Hep3B cells, while PARP
cleavage was not seen in Huh7 cells, which suggested a form of
caspase-independent death (Fig. 1E).
After DHMEQ–Olaparib treatment, the level of the anti-apoptotic
B-cell lymphoma 2 (Bcl-2) protein was reduced in Hep3B cells
(Fig. 1E), while Bcl-2 increased after DHMEQ–Olaparib treatment of
Huh7 cells, suggesting a protective effect. QPCR of Bcl2 mRNA in
Hep3B cells conﬁrmed a signiﬁcant down-regulation after combination
treatment (Fig. 1F). Interleukin-6 (IL-6) a transcriptional target of NF-κB
was down-regulated by combination treatment more than drugs used
independently (Fig. 1F right).
We evaluated apoptosis in Hep3B cells treated with DHMEQ and/or
Olaparib using the TUNEL assay (Fig. 1G). Signiﬁcantly, higher increases
in the percentage of apoptosis were observed in cells treated with
DHMEQ–Olaparib combination more than with DHMEQ or Olaparib
used independently (Fig. 1G).
Hep3B cells were analysed for the expression of pro-apoptotic
HKR protein, a BH3-only member of the Bcl-2 family that promotes72 hwith the indicated concentrations of DHMEQ–Olaparib and cell viability was assessed
ity in Hep3B cells and additive inhibition in Huh7 cells. Combination index (CI) values are
f three separate experiments (each of which was performed in triplicate). *p b 0.05 and
parib (μM) alone or in combination, allowed to grow for 14 days in the absence of drugs
nies and are the mean + SD of two separate experiments (each of which was performed
entrations of DHMEQ (μg/ml) or Olaparib (μM) alone or in combination for 24 h and cell
and are the means ± SD of three separate experiments (each of which was performed in
ergistic inhibition of cell proliferation in Hep3B and additive inhibition in Huh7 cells. The
th DHMEQ (μg/ml) or Olaparib (μM) alone or in combination, and caspase 3/7 activation
d are the means ± SD of two separate experiments, each of which was performed in trip-
(μM)alone or in combination for 24 h. The induction of PARP cleavage (85 kDa) and chang-
cl-2 differencewith vehicle-treated control samples (DMSO) arbitrarily set at 1.0. The data
lysed by q-PCR in Hep3B cells. Relative expression was calculated as ratio of drug-treated
e results shown are the means ± SD of two experiments (each performed in triplicate).
ntitative-PCR in Hep3B cells using gene-speciﬁc primers. The results were normalized to
periments. *p b 0.05 versus each agent alone. (G) Hep3B cells were treated for 24 h with
visualized by TUNEL staining as described in the Materials and methods section. (Right)
ssed as the means ± SD of two separate experiments. Magniﬁcation 20×. Scale bar =
(μg/ml) or Olaparib (μM) alone or in combination and mRNA expression levels of HKR
imentswith comparable outcomes. (I) Hep3B cells were transfectedwith a NonCorrelated
f HKR mRNA in cells transfected. 48 h after transfection. (Left) Cells were treated for 24 h
theMTS assays. The data aremean± SDof three separate experiments each ofwhichwas
2666 N. Lampiasi et al. / Biochimica et Biophysica Acta 1843 (2014) 2662–2673apoptosis through physical interaction with Bcl-2 and activation of the
mitochondria-dependent apoptosis [18,19]. Increased HKR mRNA was
seen in Hep3B cells after DHMEQ–Olaparib treatment compared with
either drug used independently (Fig. 1H). Knockdown of the HKR
gene rescued viability of Hep3B cells treatedwith the drug combination,
which indicated the involvement of HKR in the apoptosis of Hep3B cells
(Fig. 1I). These data suggested that Hep3B cells undergo apoptosis
through activation of the intrinsic apoptotic pathway, while Huh7
cells undergo caspase-independent cell death.
3.2. DHMEQ–Olaparib induced ROS production and suppressed cell
viability
DHMEQ induces ROS production, which damages DNA in hepatoma
cell lines [5,6]. In order to elucidate the role of ROS in the synergistic
effects of the DHMEQ–Olaparib combination, the production of ROS in
HCC cells was evaluated.
ROS production increased after DHMEQ–Olaparib treatment of Hep3B
(Fig. 2A), while treatment of Huh7 cells reduced ROS production to very
low levels (with respect to Hep3B cells) (data not shown). NAC reduced
the number of ﬂoating and shrunken cells after the DHMEQ–Olaparib
treatment in both cell lines, suggesting a recovery of cell viability (Fig. S2).
The presence of NAC rescued reduced cell viability in both cell lines
after DHMEQ–Olaparib treatment (Fig. 2B). These results suggested that
the DHMEQ–Olaparib combination induced ROS production in both cell
lines differently, but still more than the individual drugs used indepen-
dently, and ROS affected the cell viability of both cell lines.
3.3. DHMEQ–Olaparib treatment resulted in an accumulation of DNA
damage and decreased Rad51 DNA repair protein in Hep3B cells
PARP1 and PARP2 are involved in DNA repair, and PARP inhibition
results in the accumulation of DNA damage and DNA repair substratesA DMSO DHMEQ Olap
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The combination of Cisplatin–Olaparib is known to reduce the for-
mation of Rad51 nuclear foci [20]. Fig. 3C shows a reduction in Rad51
nuclear foci after exposure of Hep3B cells to the drug combination
(when compared with either drug used independently) while γH2AX
foci were increased (Fig. 3D). Rad51 nuclear foci did not decrease after
combination treatment of Huh7 cells, even though γH2AX foci were in-
creased (Fig. 3C & D). These results demonstrated the DHMEQ–Olaparib
combination increased DNA damage in Hep3B and Huh7 cells through
ROS production and in Hep3B cells, the combination treatment was ac-
companied by a reduction in Rad51 nuclear foci (implying reduced DNA
damage repair).
3.4. Depletion of Rad51 or PARP1 signiﬁcantly enhanced the sensitivity of
Huh7 cells to DHMEQ and DHMEQ–Olaparib
Reduction of Rad51 may have a role in the synergistic response to
DHMEQ–Olaparib by Hep3B cells (Fig. 3). Therefore, to address this
issue we depleted Rad51 and PARP1 in HCC cell lines. Western blots
showed a reduction in Rad51 and PARP1 proteins in cells transfected
with speciﬁc siRNAs (Fig. 4A). In Huh7 cells with a defective HR
(FANCD2mut), the knockdown of Rad51 and PARP1 mRNAs had an ef-
fect per se on colony formation (Fig. 4B) and cell proliferation (Fig. 4C).
Silencing of Rad51 and PARP1 mRNAs signiﬁcantly reduced colony
formation (Fig. 4B) and cell proliferation in Hep3B cells (Fig. 4C), sug-
gesting that Rad51 and PARP1 played a role in killing HCC cells.H
ep
3B
DH +Olaparib arib
Hep3B
%
 c
el
l v
ia
bi
lit
y
DHMEQ
Olaparib
-
-
15
-
-
40
15
40
**
**
0
20
40
60
80
100
120
- NAC
+NAC
50 μm
escues cell viability after drug combination treatment. (A) Hep3B cells were treated with
levels were evaluated by H2DCFDA staining. Data are representative of three different ex-
Hep3B cellswere pre-treated (2h)withNAC (2mM)before aswell as duringDHMEQ(μg/
*p b 0.01 versus each drug alone or in combination in the absence of NAC.
ADC
+NAC
B
D
A
PI
R
A
D
51
H
ep
3B
DMSO Olaparib DHMEQ DHMEQ+Olaparib
R
A
D
51
H
uh
7
D
A
PI
DMSO Olaparib DHMEQ DHMEQ+Olaparib
γH2AX
β-actin
Hep3B
-NAC
1     1.7       1       9        1       1      1       1
γH2AX
β-actin
Huh7 Hep3B
1     2      2.5     1.7      3        5 1      1.3    2.9    1.9      4      8.5
DHMEQ
Olaparib
-
-
-
40
15
-
15
20
-
20
15
40
-
-
-
40
15
-
15
20
-
20
15
40
+NAC
Huh7
-NAC
1      1.7    1.2      4       1       1       1       1
DHMEQ
Olaparib
-
-
15
40
15
-
-
40
-
40
15
40
15
-
-
-
-
-
15
40
15
-
-
40
-
40
15
40
15
-
-
-
DMSO Olaparib DHMEQ DHMEQ+Olaparib
γH
2A
X
H
uh
7
D
A
PI
D
A
PI
γH
2A
X
H
ep
3B
DMSO Olaparib DHMEQ DHMEQ+Olaparib
50 μm
50 μm
50 μm50 μm50 μm
50 μm50 μm50 μm
50 μm50 μm50 μm50 μm
50 μm50 μm50 μm50 μm
Fig. 3. DHMEQ–Olaparib combination increases γH2AX expression in both cell lines and decreases Rad51 nuclear foci in Hep3B cells. (A) Cells were treated with DHMEQ (μg/ml) or
Olaparib (μM) alone or in combination for 24 h and γH2AX, expression level was analysed bywestern blotting. The numbers represent fold of γH2AX differencewith vehicle-treated con-
trol samples (DMSO) arbitrarily set at 1.0. The data represent two independent experiments with comparable outcomes. (B) Cells were treatedwith DHMEQ or Olaparib alone or in com-
bination for 24 h, with or without pre-treatment (2 h) with NAC (2mM), and γH2AX expressionwas analysed bywestern blotting. The numbers represent fold of γH2AX difference with
vehicle-treated control samples (DMSO) arbitrarily set at 1.0. The data shown represent two independent experiments with comparable outcomes. Representative images of Rad51
(C) and γH2AX (D) nuclear foci were detected by immunoﬂuorescence in both cell lines treated with DHMEQ (15 μg/ml) or Olaparib (40 μM) alone or in combination for 24 h. Nuclei
were stained with DAPI. Magniﬁcation 20×. Scale bar = 50 μM. The data shown represent two independent experiments with comparable outcomes.
2667N. Lampiasi et al. / Biochimica et Biophysica Acta 1843 (2014) 2662–2673Interestingly, depleting Rad51 mRNA in Huh7 cells signiﬁcantly in-
creased sensitivity to DHMEQ and the DHMEQ–Olaparib combination,
leading to synergistic effects on cell proliferation inhibition (CI = 0.7)
(Fig. 4D), and the knockdown of PARP1 sensitized Hep3B and Huh7
cells to DHMEQ treatment (Fig. 4E). These results demonstrated that de-
creased Rad51 (combination therapy) played a role in HCC cell death,
and inhibition of PARP1 synergized with the effects of DHMEQ.3.5. DHMEQ–Olaparib promoted AKT1 phosphorylation in Hep3B cells
which was linked to down-regulation of Rad51 nuclear foci
Activation of AKT signalling can inhibit homologous recombination
after DNA damage through Rad51 cytoplasmic retention and reduction
of Rad51 nuclear foci [21]. As the number of Rad51 nuclear fociwere de-
creased in Hep3B cells after the DHMEQ–Olaparib treatment, the role of
AKT1 in the reduction of Rad51 nuclear foci was investigated. AKT1
phosphorylation after DHMEQ–Olaparib treatment was analysed in
Hep3B and Huh7 cells, where the combination treatment induced
AKT1 phosphorylation in Hep3B cells but not Huh7 (Fig. 5A), and
AKT1 phosphorylation was reversed by NAC, suggesting a role for ROS.
AKT1 mRNA was knocked-down in Hep3B cells to investigate its role
in decreasing Rad51 nuclear foci. Western blot analysis showed that
AKT1 was markedly reduced after gene silencing (Fig. 5C top), and de-
pletion of AKT1 mRNA restored the number of Rad51 nuclear foci in
Hep3B cells (Fig. 5C) though AKT1 mRNA silencing had no signiﬁcant
effect on cell viability (Fig. 5D). These data demonstrated that afterDHMEQ–Olaparib treatment, high levels of phosphorylated AKT1
impaired Rad51 nuclear foci in Hep3B cells.
3.6. DHMEQ–Olaparib triggered an ER stress response in Hep3B cells
DHMEQ treatment, through ROS generation, induced the splicing of
XBP1mRNA and the expression of CHOP and TRB3mRNAs,which are es-
sential for apoptosis [5]. The potential contribution of ER stress to the
synergistic/additive effects between DHMEQ and Olaparib in HCC cells
was evaluated. The DHMEQ–Olaparib combination induced the splicing
of XBP1 mRNA in Hep3B cells (Fig. 6A), while neither DHMEQ nor the
DHMEQ–Olaparib combination triggered splicing of XBP1 mRNA in
Huh7 cells. Unspliced XBP1 (XBP1u) negatively regulated XBP1 splicing
(XBP1s) andXBP1u is induced during the recovery phase of the ER stress
response, promoting cellular survival [22]. After DHMEQ–Olaparib treat-
ment, knockdown of XBP1 mRNA signiﬁcantly decreased Huh7 cell
viability (Fig. 6B). XBP1s is a transcriptional activator of the unfolded
protein response (UPR) and CHOP and its downstream target TRB3
(among others genes) are activated by XBP1s. Real-Time PCR results
showed that CHOP and TRB3 mRNAs were signiﬁcantly up-regulated in
Hep3B cells after the combination treatment, indicating an aggravated
ER stress response which was only modestly induced in Huh7 cells
(Fig. 6C). These results suggested a role for the ER stress response in
the synergistic effects of the drug combination in Hep3B cells. Knock-
down of TRB3mRNA rescuedHep3B cell viability after DHMEQ–Olaparib
treatment (Fig. 6D). These results suggested that an aggravated ER stress
response decreased cell viability in DHMEQ–Olaparib treated Hep3B
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have contributed to the additive effects of DHMEQ–Olaparib treatment
in Huh7 cells.
3.7. DHMEQ–Olaparib induced autophagy and ERK1/2 phosphorylation in
Hep3B cells
PARP1 is involved in autophagy signalling but suppresses late-stage
autophagy (such as LC3-II formation) after oxidative stress [23]. Rarely,
autophagy was persistently-activated in response to stress, but was
activated in a regulated manner to avoid autophagy-induced cell
death. The role of the DHMEQ–Olaparib combination in inducing
autophagy in HCC cells was investigated. LC3 lipidation is a marker ofautophagosome formation and is activated in late autophagy by the
Atg-7 conjugation of phosphatidylethanolamine, producing LC3-II.
Interestingly, DHMEQ and DHMEQ–Olaparib induced autophagy in
Hep3B cells while Huh7 cells had no formation of LC3-II (Fig. 7A).
Hep3B cells exposed to NAC (antioxidant/ROS scavenger) showed a de-
crease in LC3-II lipidation, which indicated that ROS generationwas key
to the induction of autophagy (Fig. 7A). (See Fig. 8.)
Stress response kinases are involved in autophagy, survival and/or
cell death after oxidative stress, and XBP1 is associated with autophagy
through ERK1/2 phosphorylation [24]. ERK1/2 was phosphorylated
in Hep3B cells after DHMEQ and DHMEQ–Olaparib treatment and
phosphorylation was dependent on ROS production since NAC
inhibited ERK1/2 phosphorylation (Fig. 7A). In contrast, there was no
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role of ERK1/2 activation in Hep3B cells, a selective MEK1/2 inhibitor
(U0126) was used. In the presence of the MEK inhibitor, ERK1/2
phosphorylation after DHMEQ–Olaparib combination treatment was
abolished in Hep3B cells (Fig. 7B), and no variations in the total amount
of ERK1/2 were seen (data not shown). U0126 alone had a signiﬁcant
inhibitory effect on the viability of untreated Hep3B cells, and signiﬁ-
cantly inhibitedHep3B cell viability after DHMEQ andDHMEQ–Olaparib
treatment, suggesting a pro-survival role for ERK1/2 phosphorylation
(Fig. 7C).
The relationship between activated ERK1/2 and autophagy in Hep3B
cells was investigated. U0126 did not prevent LC3-II formation induced
by theDHMEQ–Olaparib combination (Fig. 7B). As the role of autophagy
in cancer was controversial, the autophagy inhibitor 3-methyladenine
(3-MA) was used to clarify its role after combination drug treatment,
where 3-MA signiﬁcantly reduced cell viability after DHMEQ–Olaparibtreatment of Hep3B cells (Fig. 7D), suggesting a pro-survival role for
autophagy. These results suggested the DHMEQ–Olaparib combination
triggered ERK1/2 phosphorylation and autophagy in Hep3B cells that
appeared to exert a pro-survival effect, but could not protect Hep3B
cells from apoptosis.
4. Discussion
PARP expression is signiﬁcantly increased in human HCC tissues
compared to adjacent non-tumour tissues [25]. Many PARP inhibitors
are in clinical trials, and Olaparib has demonstrated single agent anti-
tumour activity in breast and ovarian cancer patients with germline
mutations in BRCA1/2 [26].
In the present study, HCC cell lines Huh7 and Hep3B cells were resis-
tant to Olaparib treatment with an IC50 N 100 μM, though clonogenic sur-
vival of these cell lines exhibited sensitivity toOlaparib at values similar to
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2670 N. Lampiasi et al. / Biochimica et Biophysica Acta 1843 (2014) 2662–2673those of breast cancer cells [27] and other HCC cells [28]. The use of drug
combinations for the treatment of tumours has been proposed as a ther-
apeutic strategy, to maximize pharmaceutical efﬁcacy and minimize ad-
verse events associated with individual components. The results of this
study showed that the DHMEQ–Olaparib combination treatment exerted
a synergistic inhibition of cell viability andproliferation inHep3B cells and
had an additive effect on Huh7 cells. The synergistic effects of the
DHMEQ–Olaparib combination in Hep3B cells correlated with increased
apoptosis, caspase 3/7 activities and cleavage of PARP, a caspase-3/7 tar-
get. InHep3B cells, the level of Bcl-2 (anti-apoptotic protein)was reduced
while the level of HKR mRNA expression (pro-apoptotic protein) was
enhanced by DHMEQ–Olaparib treatment.
HKR over-expression triggers ER stress through oxidative stress
[18,19] and the ER stress response was a major mechanism that medi-
ated apoptotic cell death and used as an anti-cancer strategy. The
DHMEQ–Olaparib combination induced a pronounced ER stress re-
sponse in Hep3B cells with a signiﬁcant induction in CHOP and TRB3
mRNAs as well as splicing of XBP1 mRNA. In contrast, Huh7 cell XBP1
mRNA was unspliced and CHOP and TRB3 mRNAs were modestly in-
creased, which suggested a very low stress response after combination
treatment.The spliced form of XBP1 is a transcriptional activator of genes in-
volved in the ER stress response and is a critical factor for the regulation
of genes involved in cell survival [29]. Recent studies suggest that
unsplicedXBP1 (XBP1u)may have a negative role in the unfolded protein
response (UPR), promoting the termination of the UPR in the ER stress re-
sponse and terminating transcription of target genes during the ER stress
recovery phase [30]. Silencing of the XBP1 mRNA in Huh7 cells increased
the reduced cell viability induced by DHMEQ–Olaparib. Among others,
the CHOP gene and its downstream target (TRB3 gene) were activated
by spliced XBP1 (XBP1s) and knockdown of TRB3 mRNA rescued cell
viability after DHMEQ–Olaparib treatment of Hep3B cells.
XBP1u mRNA suppresses autophagy [24]; an organized mechanism
that delivers damaged cell structures to lysosomes for degradation,
which occurs early and late, each with activation of different markers.
PARP1 is involved in autophagy signalling but it suppresses late-stage
autophagy [23]. While Huh7 cells failed to display LC3-II formation in
response to Olaparib and DHMEQ (alone or in combination), Hep3B
cells treated with DHMEQ and DHMEQ–Olaparib showed increased
autophagy.
However, the signiﬁcance of autophagy in cancer cells remains poor-
ly deﬁned, though recent studies suggest that autophagy is required for
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type II programmed cell death inHCC [32]. Autophagy can either reduce
themetabolic stress-induced DNA damage response [33] and ROS accu-
mulation [34] or induce phosphorylation of ERK1/2 and ROS production
[35].
The drug combination used in this study increased ROS generation
more than either drug alone (especially in Hep3B cells), and the ROS
scavenger NAC rescue cell viability after DHMEQ–Olaparib treatment of
cell lines. Hep3B cells had increased levels of phosphorylated ERK1/2
after treatmentwithDHMEQandDHMEQ–Olaparib,whichwas reversed
by NAC treatment.
Drug-induced phosphorylation of ERK1/2 triggers apoptosis and
autophagy in cancer cells [36,37]. In this study, the presence of a MEK
inhibitor (U0126) demonstrated that the ERK signalling pathway pro-
moted cellular survival, but did not contribute to autophagy. Autophagy
was induced by ROS after DHMEQ and DHMEQ–Olaparib treatment ofHep3B cells and played a protective role. Consistent with these data,
previous reports suggest that autophagy may be a consequence of ROS
production in response to stress conditions [38], andmay serve as a che-
motherapy defence mechanism in Hep3B cells [39].
Oxidative stress induced DNA damage and activated PARP1 and
PARP2. Activated PARP pathways resulted in DNA repair or cell death.
Olaparib increased γH2AX, a marker of DNA damage, in both cell lines,
and γH2AX protein levels and nuclear foci were increased when cells
were treated with DHMEQ–Olaparib. Recent reports show the correla-
tion between a deﬁciency in Rad51 and sensitivity to the PARP inhibitor
Olaparib [40]. DHMEQ and DHMEQ–Olaparib treatment decreased the
number of Rad51 nuclear foci in Hep3B cells. These results are in agree-
ment with other authors who report a reduction in Rad51 nuclear foci
due to the synergistic effects of a Cisplatin–Olaparib combination
[20]. In contrast, Rad51 nuclear foci were unaffected by DHMEQ and
DHMEQ–Olaparib treatment of Huh7 cells.
DHMEQ
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Fig. 8. Pathways targeted by DHMEQ–Olaparib combination on Hep3B cells. DHMEQ–Olaparib combination induced ROS production, which caused DNA damage, triggered ER stress
response and increased AKT phosphorylation. AKT phosphorylation reduced Rad51 nuclear foci. These stress signals lead to cell death, although induction of autophagy and ERK1/2 phos-
phorylation played a protective role.
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Olaparib treatment, indicating that the additive effects of the drug com-
bination did not reduce the number of Rad51 nuclear foci that could
drive DNA damage.
Accordingly, other authors found that silencing Rad51 in an
Olaparib-resistant human gastric cancer cell line increases sensitivity
to PARP inhibitors, and that decreased numbers of Rad51 nuclear foci
may hamper the DNA repair process [40]. Restoration of the Rad51 pro-
tein in an Olaparib-sensitive gastric cancer cell line attenuated PARP
inhibitor sensitivity [40].
Activation of AKT1 could retain Rad51 protein in the cytoplasm and
affect DNA damage repair by decreasing the number of nuclear foci [41].
The results of this study demonstrated that the DHMEQ–Olaparib com-
bination treatment induced AKT1 phosphorylation and decreased the
number of Rad51 nuclear foci in Hep3B cells, while silencing AKT1
mRNA in cells treated with the combination restored the number of
Rad51 nuclear foci (see Fig. 8).5. Conclusion
The ﬁndings of this study demonstrated that HCC was resistant to
PARP inhibition but responded to the DHMEQ–Olaparib combination,
and the additive or synergistic effects depended on the cellular response
rather than genetic defects linked to HR repair. This indicated that com-
bination therapy with DHMEQ–Olaparib may be a strategy for treat-
ment of PARP-resistant tumours.
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doi.org/10.1016/j.bbamcr.2014.07.010.Conﬂict of interest
The authors declare no conﬂict of interest.Funding
This work was supported in part by grants from the Italian
“Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR)” FIRB-
MERIT [RBNE08YYBM] to M.C. and G.M.; M.C. has also been supported
in part by a grant to the CNR from the Italian Ministry of Economy and
Finance for the Project FaReBio di Qualità.References
[1] B.B. Aggarwal, S. Shishodia, S.K. Sandur, M.K. Pandey, G. Sethi, Inﬂammation and
cancer: how hot is the link? Biochem. Pharmacol. 72 (2006) 1605–1621.
[2] P. Liu, E. Kimmoun, A. Legrand, A. Sauvanet, C. Degott, B. Lardeux, et al., Activation of
NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in
human hepatocellular carcinomas, J. Hepatol. 7 (2002) 63–71.
[3] D.V. Starenki, H. Namba, V.A. Saenko, A. Ohtsuru, S. Maeda, K. Umezawa, et al.,
Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor,
dehydroxymethyl-epoxyquinomicin, Clin. Cancer Res. 10 (2004) 6821–6829.
[4] D. Nishimura, H. Ishikawa, K. Matsumoto, H. Shibata, Y. Motoyoshi, M. Fukuta, et al.,
DHMEQ, a novel NF-κB inhibitor, induces apoptosis and cell-cycle arrest in human
hepatoma cells, Int. J. Oncol. 29 (2006) 713–719.
[5] N. Lampiasi, A. Azzolina, N. D'Alessandro, K. Umezawa, J.A. McCubrey, G. Montalto,
M. Cervello, Antitumor effects of dehydroxymethylepoxyquinomicin, a novel
nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through
a reactive oxygen species-dependent mechanism, Mol. Pharmacol. 76 (2009)
290–300.
[6] N. Lampiasi, A. Azzolina, K. Umezawa, G. Montalto, J.A. McCubrey, M. Cervello, The
novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumour effects
on human liver cancer cells by ROS-dependent mechanism, Cancer Lett. 322 (2012)
35–44.
[7] M.S. Satoh, T. Lindahl, Role of poly(ADP-ribose) formation in DNA repair, Nature 356
(1992) 356–358.
[8] G. Noel, C. Godon, M. Fernet, N. Giocanti, F. Megnin-Chanet, V. Favaudon,
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-
naphthalimide is speciﬁc of the S phase of the cell cycle and involves arrest of
DNA synthesis, Mol. Cancer Ther. 5 (2006) 564–574.
[9] N. Salh-Gohari, H.E. Bryant, N. Schultz, K.M. Parker, T.N. Cassel, T. Helleday, Sponta-
neous homologous recombination is induced by collapsed replication forks that
are caused by endogenous DNA single-strand breaks, Mol. Cell. Biol. 25 (2005)
7158–7169.
2673N. Lampiasi et al. / Biochimica et Biophysica Acta 1843 (2014) 2662–2673[10] H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez, et al., Speciﬁc
killing of BRCA2-deﬁcient tumours with inhibitors of poly(ADP-ribose) polymerase,
Nature 434 (2005) 913–917.
[11] H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, et al.,
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy,
Nature 434 (2005) 917–921.
[12] A.D. D'Andrea, Susceptibility pathways in Fanconi's anemia and breast cancer, N.
Engl. J. Med. 362 (2010) 1909–1919.
[13] N. McCabe, N.C. Turner, C.J. Lord, K. Kluzek, A. Bialkowska, S. Swift, et al., Deﬁciency
in the repair of DNA damage by homologous recombination and sensitivity to
poly(ADP-ribose) polymerase inhibition, Cancer Res. 66 (2006) 8109–8115.
[14] Y. Drew, R. Plummer, PARP inhibitors in cancer therapy: two modes of attack on the
cancer cell widening the clinical applications, Drug Resist. Updat. 12 (2009) 153–156.
[15] S. Kummar, A. Chen, R.E. Parchment, R.J. Kinders, J. Ji, J.E. Tomaszewski, et al.,
Advance in using PARP inhibitors to treat cancer, BMC Med. 10 (2012) 25–29.
[16] H.C. Chuang, N. Kapuriya, S.K. Kulp, C.S. Chen, C.L. Shapiro, Differential anti-
proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-
negative breast cancer cells, Breast Cancer Res. Treat. 134 (2012) 649–659.
[17] Y. Suzuki, C. Sugiyama, O. Ohno, K. Umezawa, Preparation and biological activities of
optically active dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB
inhibitor, Tetrahedran 60 (2004) 7061–7066.
[18] N. Inohara, L. Ding, S. Chen, G. Nunez, Harakiri, a novel regulator of cell death,
encodes a protein that activates apoptosis and interacts selectively with survival-
promoting proteins Bcl-2 and Bcl-X(L), EMBO J. 16 (1997) 1686–1694.
[19] J. Sunayama, Y. Ando, N. Iton, A. Tomiyama, K. Sakurada, A. Sugiyama, Physical and
functional interaction between BH3-only protein Hrk and mitochondrial pore-
forming protein p32, Cell Death Differ. 11 (2004) 771–781.
[20] D. Minami, N. Takigawa, H. Takeda, N. Ochi, E. Ichihara, A. Hisamoto, et al., Synergis-
tic effect of Olaparib with combination of Cisplatin on PTEN-deﬁcient lung cancer
cells, Mol. Cancer Res. 11 (2012) 140–148.
[21] A. Mukherjee, P. Karmakar, Attenuation of PTEN perturbs genomic stability via
activation of AKT and down-regulation of Rad51 in human embryonic kidney
cells, Mol. Carcinog. 52 (2012) 611–618.
[22] H. Yashida, M. Oku, M. Suzuki, K. Mori, pXBP1(u) encoded in XBP1 pre-mRNA
negatively regulates unfolded protein response activator pXBP1 in mammalian ER
stress response, J. Cell Biol. 172 (2006) 565–575.
[23] P. Wyrsch, C. Blenn, J. Bader, F. Althaus, Cell death and autophagy under oxidative
stress: roles of poly(ADP-ribose) polymerase and Ca2+, Mol. Cell. Biol. 32 (2012)
3541–3553.
[24] Y. Zhao, X. Li, M.Y. Cai, K. Ma, J. Yang, J. Zhou, et al., XBP-1u suppresses autophagy by
promoting the degradation of Fox01 in cancer cells, Cell Res. 23 (2013) 491–507.
[25] S. Shimizu, F. Nomura, T. Tomonaga, M. Sunaga, M. Noda, M. Ebara, et al., Expression of
poly(ADP-ribose) polymerase in humanhepatocellular carcinoma and analysis of biop-
sy specimens obtained under sonographic guidance, Oncol. Rep. 12 (2004) 821–825.
[26] N. Bundred, J. Gardovskis, J. Jaskiewiez, J. Eglitis, V. Paramovov, P. McCormack, et al.,
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor
olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer
surgery, Invest. New Drugs 31 (2013) 949–958.[27] H.C. Chuang, N. Kapuriya, S.K. Kulp, C.S. Chen, C.L. Shapiro, Differential
anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in
triple-negative breast cancer cells, Breast Cancer Res. Treat. 134 (2012) 649–659.
[28] J.X. Zhang, D.Q. Li, A.R. He, M. Motwani, V. Vasilion, J. Eswaran, et al., Synergistic in-
hibition of hepatocellular carcinoma growth by cotargeting chromatin modifying
enzymes and poly(ADP-ribose) polymerase, Hepatology 55 (2012) 1840–1851.
[29] K. Yamamoto, H. Yoshida, K. Kokame, R.J. Kaufman, K. Mori, Differential contribu-
tions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-
responsive cis-acting elements ERSE, UPRE and ERSE-II, J. Biochem. 136 (2004)
343–350.
[30] H. Yashida, M. Oku, K. Mori, pXBP1 (u) encoded in XBP1 pre-mRNA negatively
regulates unfolded protein response activator pXBP1 (s) in mammalian ER stress
response, J. Cell Biol. 172 (2006) 565–575.
[31] K. Sato, K. Tsuchihara, S. Fujiji, M. Sugiyama, T. Goya, Y. Atomi, et al., Autophagy is
activated in colorectal cancer cells and contributes to the tolerance to nutrient
deprivation, Cancer Res. 67 (2007) 9677–9684.
[32] M. Hu, H. Huang, R. Zhao, P. Li, M. Li, H. Miao, et al., AZD8055 induces cell death
associated with autophagy and activation of AMPK in hepatocellular carcinoma,
Oncol. Rep. 31 (2013) 649–656.
[33] R. Mathew, S. Kongara, B. Beaudoin, C.M. Karp, K. Bray, K. Degenhardt, Autophagy
suppresses tumor progression by limiting chromosomal instability, Genes Dev. 21
(2007) 1367–1381.
[34] K. Degenhardt, R. Mathew, B. Beaudoin, K. Bray, D. Anderson, G. Chen, et al., Autoph-
agy promotes tumor cell survival and restricts necrosis, inﬂammation and tumori-
genesis, Cancer Cell 10 (2006) 51–64.
[35] K. Gong, C. Chen, Y. Zhan, Y. Chen, Z. Huang, L. Wenhua, Autophagy-related gene 7
(ATG7) and reactive oxygen species/extracellular signal-regulated kinase regulate
tetrandrine-induced autophagy in human hepatocellular carcinoma, J. Biol. Chem.
287 (2012) 35576–35588.
[36] S. Das Gupta, B. Halder, A. Gomes, A. Gomes, Bengalin initiates autophagic cell death
through ERK–MAPK pathway following suppression of apoptosis in human
leukemic U937 cells, Life Sci. 93 (2013) 271–276.
[37] Z. Lou, T. Ren, X. Peng, Y. Sun, G. Jiao, Q. Lu, et al., Bortezomib induces apoptosis and
autophagy in osteosarcoma cells throughmitogen-activated protein kinase pathway
in vitro, J. Int. Med. Res. 41 (2013) 1505–1519.
[38] J.M. Rodriguez-Vargas, M.J. Ruiz-Magana, C. Ruiz-Ruiz, J. Majuelos-Melguizo, A.
Peralta-Leal, M.I. Rodriguez, et al., ROS-induced DNA damage and PARP1 are
required for optimal induction of stravetion-induced autophagy, Cell Res. 22
(2012) 1181–1198.
[39] X.L. Guo, D. Li, F. Hu, J. Song, S. Zhang,W. Deng, et al., Targeting autophagy potentiates
chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma
cells, Cancer Lett. 320 (2012) 171–179.
[40] A. Min, I. Sa, Y.K. Yoon, S.H. Song, H.J. Nam, H.S. Hur, et al., Rad51C-deﬁcient cancer
cells are highly sensitive to the PARP inhibitor olaparib, Mol. Cancer Ther. 12 (2013)
865–877.
[41] I. Plo, C. Laulier, L. Gauthier, F. Lebrun, F. Calvo, B.S. Lopez, AKT1 inhibits homologous
recombination by inducing cytoplasmic retention of BRCA1 and Rad51, Cancer Res.
68 (2008) 9404–9412.
